Due to these changes, the 2006 inclusion criteria (Gleason grade (GG) ≤1, clinical stage ≤T2c, PSA ≤10 ng/mL, ≤2 cores positive for PCa, PSA density ≤0.2 ng/mL/cm (3), and fitness for therapy) have been modified by allowing patients with >2 cores positive for PCa in the PRIAS study where MRI is used before diagnosis or during follow-up. Here, KLK3 is linked to posterior cortical atrophy.